» Articles » PMID: 35935615

Angiographic Severity in Acute Coronary Syndrome Patients with and Without Standard Modifiable Risk Factors

Abstract

Background: Routine coronary artery disease (CAD) secondary prevention strategies target standard modifiable cardiovascular risk factors (SMuRFs), which include: diabetes mellitus, dyslipidemia, hypertension, and smoking. However, a significant proportion of patients with acute coronary syndrome (ACS) present without any SMuRFs. The angiographic severity of disease in this population has not yet been investigated.

Methods: After propensity score matching of patients without SMuRFs and patients with ≥1 SMuRFs (ratio 1:3), we used zero-inflated negative binomial regression modeling to investigate the relationship of SMuRF-less status with the angiographic severity of CAD, as measured by the SYNTAX score. Survival analysis was performed to investigate differences in all-cause mortality at 30 days and at the end of follow-up period.

Results: We analyzed 534 patients presenting with ACS who underwent coronary angiography. Of them, 56 (10.5%) presented without any SMuRF. After propensity score matching, the median SYNTAX score was 13.8 (IQR 0-22.1) in 56 SMuRF-less patients and 14 (IQR 5-25) in 166 patients with ≥1 SMuRFs. SMuRF-less status was associated with increased odds of zero SYNTAX score [zero-part model: odds ratio = 2.11, 95% confidence interval (CI): 1.03-4.33], but not with decreased SYNTAX score among patients with non-zero SYNTAX score (count-part model: incidence rate ratio = 0.99, 95% CI: 0.79-1.24); the overall distribution of the SYNTAX score was similar between the two groups ( = 0.26). The 30-day risk for all-cause mortality was higher for SMuRF-less patients compared to patients with ≥1 SMuRFs [hazard ratio (HR) = 3.58, 95% CI: 1.30-9.88]; however, the all-cause mortality risk was not different between the two groups over a median 1.7-year follow-up (HR = 1.72, 95% CI: 0.83-3.57).

Conclusion: Among patients with ACS, the absence of SMuRFs is associated with increased odds for non-obstructive CAD and with increased short-term mortality rates.

Citing Articles

Effect of Cardiovascular Risk Factors on 30-Day All-Cause Mortality in Cardiogenic Shock.

Forner J, Schupp T, Weidner K, Ruka M, Egner-Walter S, Behnes M J Clin Med. 2023; 12(14).

PMID: 37510985 PMC: 10381971. DOI: 10.3390/jcm12144870.


Effect of obstructive sleep apnea on prognosis in patients with acute coronary syndromes with varying numbers of standard modifiable risk factors: insight from the OSA-ACS study.

Wang B, Zhang Y, Hao W, Fan J, Yan Y, Gong W J Thromb Thrombolysis. 2023; 56(1):65-74.

PMID: 37243941 PMC: 10284994. DOI: 10.1007/s11239-023-02830-w.


Association of clinical, laboratory and imaging biomarkers with the occurrence of acute myocardial infarction in patients without standard modifiable risk factors - rationale and design of the "Beyond-SMuRFs Study".

Moysidis D, Daios S, Anastasiou V, Liatsos A, Papazoglou A, Karagiannidis E BMC Cardiovasc Disord. 2023; 23(1):149.

PMID: 36959584 PMC: 10037837. DOI: 10.1186/s12872-023-03180-4.


Epicardial fat volume evaluated with multidetector computed tomography and other risk factors for prevalence of three-vessel coronary lesions.

Gao B, Li C, Liao Q, Pan T, Ren C, Cao Q Eur J Med Res. 2022; 27(1):308.

PMID: 36572947 PMC: 9793663. DOI: 10.1186/s40001-022-00956-w.

References
1.
Figtree G, Vernon S . Coronary artery disease patients without standard modifiable risk factors (SMuRFs)- a forgotten group calling out for new discoveries. Cardiovasc Res. 2021; 117(6):e76-e78. DOI: 10.1093/cvr/cvab145. View

2.
Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P . Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2019; 395(10226):795-808. PMC: 8006904. DOI: 10.1016/S0140-6736(19)32008-2. View

3.
Burgess S, Ference B, Staley J, Freitag D, Mason A, Nielsen S . Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis. JAMA Cardiol. 2018; 3(7):619-627. PMC: 6481553. DOI: 10.1001/jamacardio.2018.1470. View

4.
Mazhar J, Figtree G, Vernon S, Galougahi K, Carlo J, Nissen S . Progression of coronary atherosclerosis in patients without standard modifiable risk factors. Am J Prev Cardiol. 2021; 4:100116. PMC: 8315424. DOI: 10.1016/j.ajpc.2020.100116. View

5.
Vernon S, Coffey S, Bhindi R, Soo Hoo S, Nelson G, Ward M . Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors. Eur J Prev Cardiol. 2017; 24(17):1824-1830. DOI: 10.1177/2047487317720287. View